Breast Cancer Clinical Trial
Official title:
Breast Cancer and the Workforce: Talking to Employers and Medical Staff About Work (TEAMWork)
| NCT number | NCT03572374 |
| Other study ID # | 18-217 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | June 7, 2018 |
| Est. completion date | June 2026 |
The purpose of this study is learn more about how being treated for breast cancer affects patients' employment. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs during and after treatment. The app provides advice for patients to use when having conversations about breast cancer with their employers and their doctors. The app is called TEAMWork (Talking to Employers And Medical staff about Work). In this study, the investigators are asking breast cancer patients who are about to receive treatment or who are currently receiving treatment to tell us what aspects of the app work well, so that they can learn how to improve it.
| Status | Recruiting |
| Enrollment | 546 |
| Est. completion date | June 2026 |
| Est. primary completion date | June 2026 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: Patient Usability Testing Inclusion Criteria: - History of a cancer diagnosis - At least 18 years of age - Male or Female - The ability to give informed consent in English or Spanish - Able to use and read a smartphone (iPhone or Android) - Has a smartphone (iPhone or Android) Community Usability Testing Inclusion Criteria: - At least 18 years of age - Male or Female - The ability to give informed consent in English or Spanish - Able to use and read a smartphone (iPhone or Android) - Has a smartphone (iPhone or Android) Focus Group and Interview Inclusion Criteria: - Completed chemotherapy treatment for stage I-III breast cancer. - Age 18 to 64 (inclusive) - Female - Paid employment (full time or part time) in the three months prior to diagnosis or at time of consent to MSK protocol #10-071 (PI: Blinder) - The ability to give informed consent in English or Spanish - Able to use and read a smartphone (iPhone or Android) - Has a smartphone (iPhone or Android) For Cohort 2: - Participants was covered by Emergency Medicaid at the time of diagnosis and/or at any point during their treatment for breast cancer RCT Inclusion Criteria: - Localized invasive breast cancer (not stage 0 or stage IV) per EMR or breast cancer (not stage 0 or stage IV) per self-report for community participants - If electronic medical record does not specify stage and patient is undergoing (neo)adjuvant chemotherapy, assume stage is I, II or III - Planning to undergo or undergoing adjuvant or neoadjuvant chemotherapy per EMR or planning to undergo or undergo chemotherapy per self-report for community participants - Age 18 to 64 (inclusive) - Female - Employment statue of (full time or part time) (those who are on disability leave/medical leave, and other unique employment circumstances at the PI's dicretion are eligible) - Language preference as English or Spanish - Able to use and read a smartphone or tablet (e.g. iPad, iPhone or Android) - Has access to a smartphone or tablet (e.g. iPad, iPhone or Android) Exclusion Criteria: RCT Exclusion Criteria: - Stage 0 breast cancer (DCIS only) - Stage IV (metastatic) breast cancer - Recurrence with metastases of breast cancer - Participants or family members who are participating in MSK IHCD studies related to social determinants of health |
| Country | Name | City | State |
|---|---|---|---|
| United States | Memorial Sloan Kettering Basking Ridge (Consent and Follow-up) | Basking Ridge | New Jersey |
| United States | Lincoln Medical and Mental Health Center | Bronx | New York |
| United States | Montefiore Medical Center | Bronx | New York |
| United States | Memorial Sloan Kettering Westchester (Consent and Follow-up) | Harrison | New York |
| United States | Queens Cancer Center of Queens Hospital | Jamaica | New York |
| United States | Memorial Sloan Kettering Monmouth (Consent and Follow-up) | Middletown | New Jersey |
| United States | Memorial Sloan Kettering Bergen (Consent and Follow up) | Montvale | New Jersey |
| United States | Bellevue Hospital Center (Data Collection Only) | New York | New York |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Memorial Sloan Kettering Cancer Center |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | number of participants still employed | Talking to Employers and Medical Staff About Work (TEAMWork) the mobile application (app) is designed to educate patients and improve their communication skills with their employers and their oncology providers, thereby increasing access to work accommodations and optimizing symptom control during treatment. By increasing patients" ability to work during treatment, we believe the app will help them retain their jobs. | 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |